AbbVie (MEX:ABBV) Moat Score: 8/10 (As of Jul. 01, 2026)


MEX:ABBV AbbVie Inc MEX:ABBV
72 GF Score
Price MXN4,411.00
GF Value MXN3,710.37
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Moat Score?

AbbVie MEX:ABBV -0.84% 72 Moat Score is 8 as of Jul. 01, 2026. GuruFocus rates MEX:ABBV with a GF Score™ of 72/100 and a GF Value™ of MXN3,710.37 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,031 Drug Manufacturers companies, AbbVie ranks better than 99.71% on this metric.

AbbVie has the Moat Score of 8, which implies that the company might have Wide Moat - Clear and robust wide moat.

AbbVie has Wide Moat: AbbVie Inc possesses a robust wide moat due to its strong patent portfolio, significant R&D capabilities, and brand strength in pharmaceuticals. The company benefits from substantial pricing power, economies of scale, and regulatory barriers, ensuring durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes AbbVie might have Wide Moat - Clear and robust wide moat.

AbbVie  (MEX:ABBV) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

AbbVie Moat Score Related Terms

MEX:ABBV vs MRK, JNJ, AMGN: Moat Score Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbbVie Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Moat Score distribution charts can be found below:

* The bar in red indicates where AbbVie's Moat Score falls into.


MEX:ABBV
72GF Score
AbbVie Inc MEX:ABBV
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 8 mean?
AbbVie (MEX:ABBV) has a Moat Score of 8 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, AbbVie ranks #3 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is AbbVie's Moat Score too high?
AbbVie's current Moat Score is 8. Based on the distribution chart, AbbVie ranks #3 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AbbVie has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Moat Score compare to MRK and JNJ?
According to the Drug Manufacturers industry distribution chart, AbbVie ranks #3 out of 1031 companies for Moat Score. This places AbbVie in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. AbbVie's current Moat Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (MEX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN3,710.37, compared to a current price of MXN4,411.00 — trading 18.9% above its estimated fair value. The current Moat Score is 8. AbbVie's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For AbbVie (MEX:ABBV), the current Moat Score is 8 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (MEX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of MXN4,411.00 is trading 18.9% above its estimated GF Value™ of MXN3,710.37. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for MEX:ABBV:

  • Moat Score: 8
  • GF Value™: MXN3,710.37 vs. price of MXN4,411.00 (18.9% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
72GF Score

Get the complete analysis for MEX:ABBV

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,411.00
Price
MXN3,710.37
GF Value